Wall Street Associates’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$709K Sell
91,661
-108,739
-54% -$813K 0.47% 77
2016
Q3
$1.52M Hold
200,400
0.52% 85
2016
Q2
$1.01M Hold
200,400
0.4% 94
2016
Q1
$1.08M Hold
200,400
0.45% 90
2015
Q4
$1.44M Hold
200,400
0.41% 83
2015
Q3
$940K Sell
200,400
-154,300
-44% -$1.47M 0.18% 161
2015
Q2
$3.95M Sell
354,700
-5,800
-2% -$57.1K 0.37% 93
2015
Q1
$2.62M Sell
360,500
-6,200
-2% -$50.8K 0.25% 120
2014
Q4
$3.54M Hold
366,700
0.34% 99
2014
Q3
$3.58M Sell
366,700
-13,800
-4% -$181K 0.37% 96
2014
Q2
$6.51M Buy
380,500
+1,900
+0.5% +$27.3K 0.56% 66
2014
Q1
$6.49M Sell
378,600
-300
-0.1% -$4.79K 0.53% 71
2013
Q4
$5.49M Buy
+378,900
New +$4.93M 0.45% 79

Other funds holding VCYT

Wall Street Associates's VCYT Position: Q4 2016 in Review

Wall Street Associates reduced its Veracyte (VCYT) stake by 54% in Q4 2016, selling an estimated $813K and leaving 91,661 shares worth $709K. The position accounts for 0.47% of the portfolio, ranked #77.

Wall Street Associates first reported a position in VCYT in Q4 2013 and has held it in 13 quarters since. The position peaked at $6.51M in Q2 2014. 74 funds tracked by Wall St. Rank hold VCYT as of Q4 2016.

  • Wall Street Associates held 91,661 shares of Veracyte worth $709K as of Q4 2016.
  • Wall Street Associates sold 108,739 Veracyte shares in Q4 2016, an estimated $813K.
  • Veracyte made up 0.47% of Wall Street Associates's portfolio in Q4 2016, its #77 holding.
  • Wall Street Associates first reported a position in Veracyte in Q4 2013 and has held it in 13 quarters since.
  • Wall Street Associates's Veracyte position peaked at $6.51M in Q2 2014.
  • 74 funds tracked by Wall St. Rank held Veracyte as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.